Imaging algorithm for men with rising serum prostate-specific antigen (PSA) after local treatment of prostate cancer, American Society of Clinical Oncology (ASCO)

mets: metastatic disease; NGI: next-generation imaging; MRI: magnetic resonance imaging; PET: positron emission tomography; NaF: sodium fluoride; PSMA: prostate-specific membrane antigen; mpMRI: multiparametric magnetic resonance imaging; CT: computed tomography.
* For men for whom salvage local therapy (eg, salvage radiation, salvage prostatectomy) is an option, there is evidence supporting the use of NGI to assess local or distant sites of disease, which may guide therapy away from salvage local therapy if indicative of distant metastatic disease.
¶ There is enthusiasm for the potential added value of PSMA PET/CT and PET/MRI for the assessment of the local and metastatic extent of prostate cancer in this context, although PSMA imaging is not currently US Food and Drug Administration (FDA)-approved and should thus be only performed as part of a clinical trial or other controlled research setting.